Is ImmunityBio, Inc. (NASDAQ:IBRX) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating ImmunityBio, Inc. at current levels.
Anktiva is quietly building a bladder cancer monopoly while 34% short interest stays anchored to a cash-burn story that no longer fits.
Where IBRX is headed
Picture late 2027. Anktiva is doing $900M to $1.1B in annual revenue, urologists across the US have written it into the standard playbook for BCG-unresponsive non-muscle invasive bladder cancer, and the label has expanded into BCG-naive disease where the addressable patient pool roughly triples. ImmunityBio is approaching operating breakeven on the commercial business, the Serum Institute partnership has cut BCG supply risk that capped uptake for years, and the lymphoma and solid tumor readouts have given the market a second leg to underwrite. The stock is no longer a binary biotech bet, it is a specialty oncology commercial story with a pipeline kicker.
Read the full Compass Direction on IBRX
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $7.25).
See the full IBRX analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is ImmunityBio, Inc. (NASDAQ:IBRX) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating ImmunityBio, Inc. at current levels. Anktiva is quietly building a bladder cancer monopoly while 34% short interest stays anchored to a cash-burn story that no longer fits.
What is IBRX's Compass Score?
ImmunityBio, Inc. scores 87/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for IBRX?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the IBRX page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.